Vetoquinol has launched a pain monitoring system along similar lines to those used in humans, which can be used by vets and owners to measure pain over time and assess different treatment strategies in dogs.  

According to the company, it is widely accepted that all mammals experience pain¹and that under treatment is a big issue. Guidelines in treating human pain issued by NICE state that: 'evidence suggests that pain caused by advanced disease remains under-treated'. Veterinary medicine faces a harder task in recognising and treating pain effectively as it relies on behaviour rather than verbal communication.

In human medicine, Client Specific Outcome Measures have been used to assess treatment strategies focussing on identifying the degree of difficulty performing daily tasks on an individual patient to patient basis. Vetoquinol says its pain monitoring system is based on similar principles.

Robert Simpson, Product Manager for Cimalgex said: "The objective assessment of clinical outcomes are a continuing challenge in veterinary medicine; this is particularly true in chronic painful conditions such as osteoarthritis. Use of our Client Specific Outcome Measures form will allow vets and pet owners to more efficiently assess treatment to ensure that the patient is receiving appropriate analgesia.

The form can be adapted to give bespoke outcome measures which are agreed in consultation with the owners. This activity will increase interaction with pet owners and could increase loyalty to the practice; it could also be really useful in geriatric clinics etc as a method of assessing pain outside of consultations in practices."

To find out more or to request a monitoring pad for your practice, contact your Vetoquinol Territory Manager or call 01280 825424.

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.